Recent
studies have linked PPIs to greater risk of fractures and kidney
disease. Some studies also have linked PPIs to an increased risk for dementia
among older adults, though several experts have questioned whether these
studies correctly measured the connection.

Research (PDF) published
in the Journal of the American
Geriatrics Society 
appears to challenge those earlier
findings.

University
of Washington (UW) School of Pharmacy Plein Center for Geriatric Pharmacy
Director and Shirley & Herb Bridge Endowed Professor Shelly Gray, along
with other researchers at the University of Washington School of Pharmacy and
Kaiser Permanente Washington Research Institute, reviewed information from the
joint UW-Kaiser Permanente Adult Changes in Thought (ACT) study, which
included 3484 subjects 65 and older. Information from the electronic pharmacy
records was used to see how many participants took PPIs, and for how long.

Overall,
nearly one in four participants developed dementia, including 670 with
possible or probable Alzheimer’s disease.  People with the heaviest use of
PPIs – equivalent to five years of daily use at typical doses – did not
have a higher risk of developing dementia than those with no PPI use.

“While some other safety concerns with
long-term PPI use might be real, results from our study suggest that dementia
is not linked to taking a PPI,” Gray said.

Source: https://sop.washington.edu/uwkaiser-study-finds-taking-proton-pump-inhibitors-not-linked-to-higher-dementia-risk/

Reference: Gray S, et al. Proton Pump
Inhibitor Use and Dementia Risk: Prospective Population-Based Study. 
Journal of the American Geriatrics Society. Published 14
November 2017. http://onlinelibrary.wiley.com/doi/10.1111/jgs.15073/epdf